|
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). |
|
|
Honoraria - Astellas Pharma; Janssen Oncology |
Consulting or Advisory Role - Bayer; Millennium |
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis |
|
|
|
Consulting or Advisory Role - Clovis Oncology |
Research Funding - AstraZeneca; Clovis Oncology; GlaxoSmithKline (Inst); Zenith Epigenetics |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Merck |
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; GenomeDx; Janssen; Myriad Pharmaceuticals; Pacific Edge Biotechnology |
Speakers' Bureau - Astellas Pharma; Dendreon; GenomeDx; Janssen; Myriad Pharmaceuticals; Pacific Edge Biotechnology |
Research Funding - Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Janssen; Myriad Pharmaceuticals |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME |
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio |
Expert Testimony - Celgene; sanofi |
|
|
No Relationships to Disclose |
|
|
Leadership - Asterias Biotherapeutics |
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Ferring; Janssen Research & Development; Merck; Onclive; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group |
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Travel, Accommodations, Expenses - Asterias Biotherapeutics; Ferring; Onclive; Physicans' Education Resource; WIRB-Copernicus Group |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology; United Health Group |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
Consulting or Advisory Role - Redwood Bioscience |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
Honoraria - GlaxoSmithKline; Novartis |
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi |
Speakers' Bureau - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi |
Research Funding - Johnson & Johnson; Sanofi |